Cargando…

The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review

Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is commonly used as an anesthetic and analgesic but has recently shown promising research in treating certain psychiatric conditions such as depression, post-traumatic stress disorder (PTSD), suicidal ideation, and substance use d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sepulveda Ramos, Carolina, Thornburg, Matthew, Long, Kelly, Sharma, Kiran, Roth, Julia, Lacatusu, Diana, Whitaker, Reece, Pacciulli, Daniel, Moredo Loo, Sulma, Manzoor, Mohammad, Tsang, Yun-Yee, Molenaar, Sydney, Sundar, Karthikeyan, Jacobs, Robin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053551/
https://www.ncbi.nlm.nih.gov/pubmed/35505747
http://dx.doi.org/10.7759/cureus.23647
_version_ 1784697005115703296
author Sepulveda Ramos, Carolina
Thornburg, Matthew
Long, Kelly
Sharma, Kiran
Roth, Julia
Lacatusu, Diana
Whitaker, Reece
Pacciulli, Daniel
Moredo Loo, Sulma
Manzoor, Mohammad
Tsang, Yun-Yee
Molenaar, Sydney
Sundar, Karthikeyan
Jacobs, Robin J
author_facet Sepulveda Ramos, Carolina
Thornburg, Matthew
Long, Kelly
Sharma, Kiran
Roth, Julia
Lacatusu, Diana
Whitaker, Reece
Pacciulli, Daniel
Moredo Loo, Sulma
Manzoor, Mohammad
Tsang, Yun-Yee
Molenaar, Sydney
Sundar, Karthikeyan
Jacobs, Robin J
author_sort Sepulveda Ramos, Carolina
collection PubMed
description Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is commonly used as an anesthetic and analgesic but has recently shown promising research in treating certain psychiatric conditions such as depression, post-traumatic stress disorder (PTSD), suicidal ideation, and substance use disorder. Due to its euphoric, dissociative, and hallucinogenic properties, ketamine has been abused as a recreational drug, which has led to rigid regulation of medication. The COVID-19 pandemic has been an unprecedented challenge for the American population which was reflected in increased reports of problems regarding their mental health. Mood disorders have dramatically increased in the past two years. Approximately one in ten people stated that they had started or increased substance use because of the COVID-19 pandemic. Furthermore, rates of suicidal ideation have significantly increased when compared to pre-pandemic levels, with more than twice the number of adults surveyed in 2018 indicating suicidal thoughts “within the last 30 days” at the time they were surveyed. Moreover, many responders indicated they had symptoms of PTSD. The PubMed database was searched using the keyword “ketamine,” in conjunction with “depression,” “suicidal ideation,” “substance use disorder,” and “post-traumatic stress disorder.” The inclusion criteria encompassed articles from 2017 to 2022 published in the English language that addressed the relationship between ketamine and mental health disorders. With this sharp increase in the prevalence of psychiatric disorders and an increased public interest in mental health combined with the promise of the therapeutic value of ketamine for certain mental health conditions, including suicidal ideation, this narrative review sought to identify recently published studies that describe the therapeutic uses of ketamine for mental health. Results of this review indicate that ketamine’s therapeutic effects offer a potential alternative treatment for depression, suicidal ideation, substance use disorders, and PTSD.
format Online
Article
Text
id pubmed-9053551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-90535512022-05-02 The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review Sepulveda Ramos, Carolina Thornburg, Matthew Long, Kelly Sharma, Kiran Roth, Julia Lacatusu, Diana Whitaker, Reece Pacciulli, Daniel Moredo Loo, Sulma Manzoor, Mohammad Tsang, Yun-Yee Molenaar, Sydney Sundar, Karthikeyan Jacobs, Robin J Cureus Psychiatry Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is commonly used as an anesthetic and analgesic but has recently shown promising research in treating certain psychiatric conditions such as depression, post-traumatic stress disorder (PTSD), suicidal ideation, and substance use disorder. Due to its euphoric, dissociative, and hallucinogenic properties, ketamine has been abused as a recreational drug, which has led to rigid regulation of medication. The COVID-19 pandemic has been an unprecedented challenge for the American population which was reflected in increased reports of problems regarding their mental health. Mood disorders have dramatically increased in the past two years. Approximately one in ten people stated that they had started or increased substance use because of the COVID-19 pandemic. Furthermore, rates of suicidal ideation have significantly increased when compared to pre-pandemic levels, with more than twice the number of adults surveyed in 2018 indicating suicidal thoughts “within the last 30 days” at the time they were surveyed. Moreover, many responders indicated they had symptoms of PTSD. The PubMed database was searched using the keyword “ketamine,” in conjunction with “depression,” “suicidal ideation,” “substance use disorder,” and “post-traumatic stress disorder.” The inclusion criteria encompassed articles from 2017 to 2022 published in the English language that addressed the relationship between ketamine and mental health disorders. With this sharp increase in the prevalence of psychiatric disorders and an increased public interest in mental health combined with the promise of the therapeutic value of ketamine for certain mental health conditions, including suicidal ideation, this narrative review sought to identify recently published studies that describe the therapeutic uses of ketamine for mental health. Results of this review indicate that ketamine’s therapeutic effects offer a potential alternative treatment for depression, suicidal ideation, substance use disorders, and PTSD. Cureus 2022-03-30 /pmc/articles/PMC9053551/ /pubmed/35505747 http://dx.doi.org/10.7759/cureus.23647 Text en Copyright © 2022, Sepulveda Ramos et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Psychiatry
Sepulveda Ramos, Carolina
Thornburg, Matthew
Long, Kelly
Sharma, Kiran
Roth, Julia
Lacatusu, Diana
Whitaker, Reece
Pacciulli, Daniel
Moredo Loo, Sulma
Manzoor, Mohammad
Tsang, Yun-Yee
Molenaar, Sydney
Sundar, Karthikeyan
Jacobs, Robin J
The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title_full The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title_fullStr The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title_full_unstemmed The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title_short The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
title_sort therapeutic effects of ketamine in mental health disorders: a narrative review
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053551/
https://www.ncbi.nlm.nih.gov/pubmed/35505747
http://dx.doi.org/10.7759/cureus.23647
work_keys_str_mv AT sepulvedaramoscarolina thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT thornburgmatthew thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT longkelly thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT sharmakiran thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT rothjulia thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT lacatusudiana thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT whitakerreece thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT pacciullidaniel thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT moredoloosulma thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT manzoormohammad thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT tsangyunyee thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT molenaarsydney thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT sundarkarthikeyan thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT jacobsrobinj thetherapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT sepulvedaramoscarolina therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT thornburgmatthew therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT longkelly therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT sharmakiran therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT rothjulia therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT lacatusudiana therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT whitakerreece therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT pacciullidaniel therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT moredoloosulma therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT manzoormohammad therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT tsangyunyee therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT molenaarsydney therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT sundarkarthikeyan therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview
AT jacobsrobinj therapeuticeffectsofketamineinmentalhealthdisordersanarrativereview